IP Library Granted Patent US 11,511,252
Granted Patent B2
US 11,511,252 · App. 16/590,093 · Granted Nov 29, 2022

Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)

Inventors: David H. Fine (Cocoa Beach, FL); David P. Rounbehler (Lexington, MA); Gregory Vasquez (Cocoa, FL); Bryan Johnson (Orlando, FL)
Assignee: VERO Biotech Inc.
B01J12/007A61K33/00A61M16/10A61M16/122A62B7/08C01B21/24A61M2016/1025A61M2202/0007A61M2202/0078A61M2202/0275A61M2205/07A61M2205/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,511,252
App. No.
16/590,093
Granted
Nov 29, 2022
Kind
B2
Abstract

A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

Claims (20)

1. A system, comprising:

a pressure regulator configured to diffuse gaseous nitrogen dioxide into an air flow, the pressure regulator including a diffusion cell configured to be connected to a source of the gaseous nitrogen dioxide; and

a receptacle fluidically coupled to the pressure regulator, the receptacle including a surface-active material coated with an aqueous solution of an antioxidant configured to convert the gaseous nitrogen dioxide to nitric oxide.

2. A system, comprising:

a pressure regulator configured to diffuse gaseous nitrogen dioxide into an air flow;

a receptacle fluidically coupled to the pressure regulator, the receptacle including a surface-active material coated with an aqueous solution of an antioxidant configured to convert the gaseous nitrogen dioxide to nitric oxide; and

a cartridge disposed downstream of the receptacle and configured to remove nitrogen dioxide from the air flow.

3. The system of claim 2 , wherein the cartridge includes activated alumina.

4. The system of claim 2 , further comprising:

a sample valve coupled to the cartridge and configured to provide samples of the air flow; and

a sensor fluidically coupled to the sample valve, the sensor configured to detect nitrogen dioxide present in the samples of the air flow.

5. A system, comprising:

a diffusion cell configured to diffuse gaseous nitrogen dioxide into an airflow;

a receptacle fluidically coupled to the diffusion cell, the receptacle including a surface-active material wetted with an aqueous solution of an antioxidant configured to convert the gaseous nitrogen dioxide to nitric oxide; and

a cartridge downstream of the receptacle, the cartridge configured to remove nitrogen dioxide from the air flow.

6. The system of claim 5 , wherein the antioxidant includes ascorbic acid.

7. The system of claim 5 , wherein the cartridge includes activated alumina.

8. The system of claim 5 , further comprising:

a sample valve coupled to the cartridge and configured to provide samples of the air flow; and

a sensor fluidically coupled to the sample valve, the sensor configured to detect nitrogen dioxide present in the samples of the air flow.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: FINE, DAVID H.; ROUNBEHLER, DAVID P.; VASQUEZ, GREGORY; JOHNSON, BRYAN
To: GENO LLC
Reel/Frame 055339/0723 →
CHANGE OF NAME Recorded Feb 19, 2021
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 055346/0795 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
Continuity (7)
Continuation 16149092 · Oct 1, 2018
Continuation 15229105 · Aug 4, 2016
Continuation 14270260 · May 5, 2014
Continuation 13436018 · Mar 30, 2012
Continuation 12563662 · Sep 21, 2009
Provisional Application 61098974 · Sep 22, 2008
Related Publication 20200282375A1 · Sep 10, 2020